Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature
- 283 Downloads
Our aim was to report our experiences of pediatric macrophage activation syndrome (MAS) patients treated with anakinra and to review previous studies reporting anakinra treatment in pediatric MAS patients associated with systemic juvenile idiopathic arthritis (sJIA) or autoinflammatory diseases (AIDs). The study group consisted of pediatric MAS patients due to sJIA or AIDs, followed up in the Pediatric Rheumatology Unit of Hacettepe University between January 2015 and January 2017 and treated with anakinra (anti-IL1). We conducted a systematic review of the published literature involving pediatric MAS patients associated with sJIA or AIDs, treated with anakinra. Thirteen sJIA patients and two AIDs patients were included the study. Nineteen MAS episodes were observed in 15 patients. Anakinra (2 mg/kg/day) was started in with a median 1 day after admission. Clinical symptoms resolved, and laboratory findings normalized within median (minimum–maximum) 2 (1–4) and 6 (4–9) days, respectively after the introduction of anakinra. Steroid treatment was stopped in a median of 10 (4–13) weeks after the initiation of anakinra treatment. Patients were followed up for a median of 13 (6–24) months. Two patients developed recurrent MAS episodes when the anakinra dose was reduced, while the other patients achieved remission. In the literature review, we identified nine articles, describing 35 pediatric MAS patients associated with sJIA or AIDs and treated with anakinra. Except for two, all the patients reached remission. Our study and systematic literature review may help to improve the knowledge on the role of anakinra treatment in the management of MAS.
KeywordsAnakinra Auto-inflammatory syndromes Juvenile idiopathic arthritis Macrophage activation syndrome
Hafize Emine Sönmez conceptualized and designed the study, carried out the initial analyses, and approved the final manuscript as submitted. Selcan Demir and Yelda Bilginer helped designing the study, collected the data, drafted the initial manuscript, and approved the final manuscript as submitted. Seza Özen coordinated and supervised data collection, reviewed and revised the manuscript, and approved the final manuscript as submitted. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
Compliance with ethical standards
- 5.Ozen S, Kuemmerle-Deschner JB, Cimaz R, Livneh A, Quartier P, Kone-Paut I, Zeft A, Spalding S, Gul A, Hentgen V, Savic S, Foeldvari I, Frenkel J, Cantarini L, Patel D, Weiss J, Marinsek N, Degun R, Lomax KG, Lachmann HJ (2017) International retrospective chart review of treatment patterns in severe familial mediterranean fever, tumor necrosis factor receptor-associated periodic syndrome, and mevalonate kinase deficiency/hyperimmunoglobulinemia D syndrome. Arthritis Care Res 69:578–586CrossRefGoogle Scholar
- 9.Ravelli A, Minoia F, Davi S et al (2016) Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against rheumatism/American College of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative. Annals Rheum Dis 75:481–489CrossRefGoogle Scholar
- 11.Minoia F, Bovis F, Davi S et al (2017) Development and initial validation of the macrophage activation syndrome/primary hemophagocytic lymphohistiocytosis score, a diagnostic tool that differentiates primary Hemophagocytic lymphohistiocytosis from macrophage activation syndrome. J Pediatr 189:72–78.e3CrossRefPubMedGoogle Scholar
- 15.Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ (2011) Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology 50:417–419CrossRefPubMedGoogle Scholar
- 25.Demirkaya E, Ozen S, Bilginer Y, Ayaz NA, Makay BB, Unsal E, Erguven M, Poyrazoglu H, Kasapcopur O, Gok F, Akman S, Balat A, Cavkaytar O, Kaya B, Duzova A, Ozaltin F, Topaloglu R, Besbas N, Bakkaloglu A, Arisoy N, Ozdogan H, Bakkaloglu S, Turker T (2011) The distribution of juvenile idiopathic arthritis in the eastern Mediterranean: results from the registry of the Turkish Paediatric Rheumatology Association. Clin Exp Rheumatol 29:111–116PubMedGoogle Scholar
- 27.Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, Hanrahan PS, Kraishi MM, Patel A, Sun G, Bear MB, 990145 Study Group (2004) A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 63:1062–1068CrossRefPubMedPubMedCentralGoogle Scholar